← The Wire
REPLNasdaq
Replimune Group, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1737953
Replimune develops oncolytic immunotherapies to activate the immune system against cancer
$733M
Market cap
$11.20
Last close
-3.7%
1D
+0.2%
5D
3.7M
Volume
Price · last 39 sessions+269.6%
May 4L $2.87 · H $11.63Jun 29
182
Total filings
Jun 29, 2026
Last filing
03/31
Fiscal year end
10-K10-KJun 29, 20268-KResults of OperationsJun 29, 20268-KReg FD DisclosureJun 26, 20268-KReg FD DisclosureMay 29, 20268-KReg FD Disclosure · Company UpdateApr 13, 202610-Q10-QFeb 3, 20268-KMaterial Agreement · Results of OperationsFeb 3, 20268-KReg FD DisclosureJan 12, 20268-KResults of OperationsNov 6, 202510-Q10-QNov 6, 20258-KCompany UpdateOct 20, 20258-KReg FD Disclosure · Company UpdateSep 18, 20258-KShareholder Vote · Reg FD DisclosureSep 4, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 2025DEFA14ADEFA14AJul 25, 2025DEF 14ADEF 14AJul 25, 20258-KReg FD Disclosure · Company UpdateJul 22, 20258-KReg FD DisclosureJun 24, 202510-K10-KMay 22, 20258-KResults of OperationsMay 22, 20258-KExecutive Change · Material AgreementMar 7, 202510-Q10-QFeb 12, 20258-KResults of OperationsFeb 12, 20258-KCompany UpdateJan 22, 20258-K/ACompany UpdateDec 4, 20248-KCompany UpdateNov 27, 2024424B5424B5Nov 26, 20248-KCompany UpdateNov 26, 2024424B5424B5Nov 25, 20248-KReg FD Disclosure · Company UpdateNov 21, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 20248-KShareholder VoteSep 5, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 2024DEFA14ADEFA14AJul 19, 2024DEF 14ADEF 14AJul 19, 20248-KMaterial Agreement · Equity IssuanceJun 13, 20248-KReg FD Disclosure · Company UpdateJun 6, 20248-KCompany UpdateJun 3, 202410-K10-KMay 16, 20248-KResults of OperationsMay 16, 20248-KExecutive Change · Company UpdateMar 26, 2024SC 13GMS INITIALFeb 9, 202410-Q10-QFeb 8, 20248-KResults of OperationsFeb 8, 2024SC 13GSC 13GJan 25, 20248-KReg FD Disclosure · Company UpdateJan 8, 20248-KMaterial Agreement · New Debt / ObligationDec 26, 20238-KCompany UpdateDec 5, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KExecutive Change · Reg FD DisclosureSep 19, 20238-KShareholder VoteSep 7, 20238-KMaterial Agreement · Agreement TerminatedAug 3, 202310-Q10-QAug 3, 20238-KResults of Operations · Reg FD DisclosureAug 3, 2023DEFA14ADEFA14AJul 26, 2023DEF 14ADEF 14AJul 26, 20238-KExecutive Change · Reg FD DisclosureJul 20, 20238-KExecutive Change · Reg FD DisclosureJun 5, 202310-K10-KMay 18, 20238-KExecutive Change · Results of OperationsMay 18, 20238-KReg FD DisclosureFeb 27, 2023SC 13GSC 13GFeb 14, 202310-Q10-QFeb 9, 20238-KResults of OperationsFeb 9, 2023SC 13GSC 13GFeb 3, 20238-KReg FD DisclosureJan 4, 20238-KCompany UpdateDec 12, 2022424B5424B5Dec 12, 2022424B5424B5Dec 7, 20228-KCompany UpdateDec 7, 202210-Q10-QNov 3, 20228-KResults of OperationsNov 3, 20228-KMaterial Agreement · New Debt / ObligationOct 7, 20228-KShareholder VoteSep 8, 202210-Q10-QAug 4, 20228-KResults of OperationsAug 4, 2022
Insider Activity
In the 90 days to Dec 9, 2025: 4 sold $258K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 9, 2025 | Dhingra KapilDirector | Sell | 3,169 | $10.40 | $33K |
| Dec 2, 2025 | Patel SushilChief Executive Officer | Sell | 10,000 | $11.13 | $111K |
| Nov 17, 2025 | Xynos KonstantinosChief Medical Officer | Sell | 7,248 | $9.10 | $66K |
| Nov 17, 2025 | Sarchi ChristopherChief Commercial Officer | Sell | 5,208 | $9.10 | $47K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance